Zhuge Hui, Ge Zhiwei, Wang Jiaojiao, Yao Jianbiao, He Jiayu, Wang Yi, Wang Yingchao, Tang Yu
Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou 310018, China.
Pharmaceuticals (Basel). 2023 Dec 28;17(1):56. doi: 10.3390/ph17010056.
Prostatitis, a prevalent urinary tract disorder in males, has a complex etiology that leads to severe clinical discomfort. Pule'an Tablets, a classic single-component formulation primarily based on rapeseed pollen, have been clinically proven to have a beneficial therapeutic effect on both prostatitis and benign prostatic hyperplasia. However, there is currently a lack of research on the chemical composition and mechanisms of action of Pule'an Tablets in treating prostatitis. In this study, using liquid chromatography-mass spectrometry (LC-MS), a total of 53 compounds in Pule'an Tablets were identified, including flavonoids, phenylpropionamides, lipids, glucosinolates, and nucleic acids. Subsequently, through a network pharmacology analysis, potential target genes and their mechanisms of action were predicted accordingly. The results suggested that genes such as LPAR5, LPAR6, LPAR4, LPAR3, LPAR2, LPAR1, F2, ENPP2, MMP9, and TNF, along with pathways like prostate cancer, endocrine resistance, bladder cancer, and the IL-17 signaling pathway, may represent potential pathways involved in the therapeutic effects of Pule'an Tablets. This study represents the first systematic investigation into the chemical composition of Pule'an Tablets, shedding light on the potential mechanisms underlying their efficacy in treating prostatitis. These findings could serve as a valuable reference for future pharmacological research on Pule'an Tablets.
前列腺炎是男性常见的泌尿系统疾病,其病因复杂,会导致严重的临床不适。普乐安片是一种主要以油菜花粉为基础的经典单成分制剂,临床已证明其对前列腺炎和良性前列腺增生均有有益的治疗作用。然而,目前关于普乐安片治疗前列腺炎的化学成分及作用机制缺乏研究。在本研究中,采用液相色谱 - 质谱联用(LC - MS)技术,共鉴定出普乐安片中53种化合物,包括黄酮类、苯丙酰胺类、脂质、硫代葡萄糖苷和核酸。随后,通过网络药理学分析,相应地预测了潜在的靶基因及其作用机制。结果表明,如LPAR5、LPAR6、LPAR4、LPAR3、LPAR2、LPAR1、F2、ENPP2、MMP9和TNF等基因,以及前列腺癌、内分泌抵抗、膀胱癌和IL - 17信号通路等途径可能是普乐安片发挥治疗作用的潜在途径。本研究是对普乐安片化学成分的首次系统研究,揭示了其治疗前列腺炎疗效的潜在机制。这些发现可为今后普乐安片的药理学研究提供有价值的参考。